Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCAVINGER: Intra-arterial Verapamil and Citicoline for Acute Ischemic Stroke
NCT02823106Phase 1Withdrawn
- Start
- Aug 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in ischemic stroke comparing Verapamil and Citicoline with Placebo (2 arms). Primary endpoint: Number of participants having no symptomatic intracranial hemorrhage at 48 hours. Planned start Aug 2016; status: withdrawn.
02
Drugs
citicolineverapamil
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02823106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02823106.